nipocalimab

nipocalimab
Routes of administration	Intravenous infusion
Synonyms	M281

nipocalimab is a high-affinity, fully human, aglycosylated, effectorless monoclonal antibody designed to selectively target and block the neonatal Fc receptor (FcRn). Developed by Johnson & Johnson through its subsidiary Janssen Pharmaceuticals, it represents a novel therapeutic approach for reducing pathogenic IgG antibodies in various autoimmune and alloimmune disorders. By inhibiting FcRn, the drug aims to lower overall IgG levels, including autoantibodies, without broadly suppressing the immune system.

Mechanism of action

nipocalimab functions by binding with high specificity to the neonatal Fc receptor at the pH of the blood plasma, preventing its interaction with Immunoglobulin G. This receptor, expressed on cells like endothelial cells and phagocytes, is crucial for recycling IgG and extending its serum half-life. By blocking this interaction, nipocalimab disrupts the salvage pathway, leading to increased catabolism of all IgG subclasses in the lysosome. This mechanism results in a rapid and sustained reduction in circulating pathogen- and autoantibody-mediated IgG levels. Unlike other immunosuppressants, its action is targeted, sparing other components of the adaptive immune system such as IgM, IgA, and IgE.

Clinical trials

The development of nipocalimab has been advanced through a broad clinical program across multiple conditions. Key studies include the Phase 2 DAFNE trial for warm autoimmune hemolytic anemia and the UNITY trial for pemphigus vulgaris. It is also being evaluated in Phase 3 studies for generalized myasthenia gravis (the VIVACITY trial) and hemolytic disease of the fetus and newborn (the UNITY trial). Further investigations are ongoing for diseases like chronic inflammatory demyelinating polyneuropathy, Sjögren's syndrome, and rheumatoid arthritis. These trials are conducted globally at major medical centers like the Mayo Clinic and in collaboration with networks such as the Myasthenia Gravis Foundation of America.

Medical uses

While still under investigation and not yet approved by regulatory bodies like the U.S. Food and Drug Administration or the European Medicines Agency, nipocalimab is being studied for its potential in treating IgG-mediated disorders. Its primary target indications include reducing harmful alloantibodies in hemolytic disease of the fetus and newborn and depleting autoantibodies in conditions like generalized myasthenia gravis and warm autoimmune hemolytic anemia. The therapeutic goal is to provide a targeted treatment that mitigates disease activity without the broad immunosuppression associated with therapies like rituximab or corticosteroids.

Adverse effects

In clinical trials, the most commonly reported adverse events have been generally mild to moderate. These include headache, urinary tract infection, and infusion-related reactions. Due to its mechanism of action, a predictable and dose-dependent reduction in serum IgG levels is observed, which may potentially increase the risk of certain infections. However, the preserved levels of other immunoglobulins and vaccine-induced immune responses, as studied with tetanus and pneumococcal vaccines, may mitigate this risk. Monitoring for hypogammaglobulinemia is a component of clinical management.

Development history

nipocalimab, originally designated M281, was discovered by MorphoSys AG using its proprietary HuCAL technology. The development rights were subsequently acquired by Johnson & Johnson in a significant collaboration. The drug received Fast Track designation from the U.S. Food and Drug Administration for both hemolytic disease of the fetus and newborn and warm autoimmune hemolytic anemia. It has also been granted Orphan Drug designation in the United States and the European Union for several conditions, including myasthenia gravis. Its development is a focal point within Janssen Pharmaceuticals' immunology portfolio.

Pharmacology

nipocalimab is administered via intravenous infusion. Its pharmacodynamics are characterized by a rapid reduction in total IgG levels, with effects observed within days of the first dose. The pharmacokinetics are linear, with an extended half-life that supports intermittent dosing regimens. As an aglycosylated antibody, it lacks Fc effector function, minimizing the risk of antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity against cells expressing FcRn. This design enhances its safety profile by focusing its action solely on FcRn blockade in the endothelium.

Category:Monoclonal antibodies Category:Experimental drugs